Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide)
作者： Chang Xia , Roberto Leon-Ferre , Douglas Laux , Jeremy Deutsch , Brian J. Smith
DOI: 10.1007/S00280-014-2501-1
关键词:
摘要: Purpose To explore the safety and tolerability of combining two epigenetic drugs: decitabine (a DNA methyltransferase inhibitor) panobinostat histone deacetylase inhibitor), with chemotherapy temozolomide (an alkylating agent). The purpose such combination is to evaluate use priming overcome resistance melanoma chemotherapy.
springer.com
core.ac.uk
paperity.org参考文章(43)
J. Treisman, M. Herlyn, S. A. Rosenberg, B. Johnson, J. Weber, D. Samid, M. Salgaller, N. Lassam, Expression of the MAGE-1 Tumor Antigen Is Up-Regulated by the Demethylating Agent 5-Aza-2′-Deoxycytidine Cancer Research. ,vol. 54, pp. 1766- 1771 ,(1994)
Jeffrey F. Waring, Keith B. Glaser, Joshua Stender, Michael J. Staver, Steven K. Davidsen, Roger G. Ulrich, Gene Expression Profiling of Multiple Histone Deacetylase (HDAC) Inhibitors: Defining a Common Gene Set Produced by HDAC Inhibition in T24 and MDA Carcinoma Cell Lines Molecular Cancer Therapeutics. ,vol. 2, pp. 151- 163 ,(2003)
Rudolf Jaenisch, Adrian Bird, Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals Nature Genetics. ,vol. 33, pp. 245- 254 ,(2003) , 10.1038/NG1089
Sandra Coral, Luca Sigalotti, Alessia Covre, Hugues JM Nicolay, Pier Giorgio Natali, Michele Maio, None, 5-AZA-2'-deoxycytidine in cancer immunotherapy: a mouse to man story. Cancer Research. ,vol. 67, pp. 2900- 2900 ,(2007) , 10.1158/0008-5472.CAN-06-2986
Oscar Alcazar, Susan Achberger, Wayne Aldrich, Zhenbo Hu, Soledad Negrotto, Yogen Saunthararajah, Pierre Triozzi, Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo International Journal of Cancer. ,vol. 131, pp. 18- 29 ,(2012) , 10.1002/IJC.26320
Joseph DeSimone, Mabel Koshy, Louise Dorn, Donald Lavelle, Linda Bressler, Robert Molokie, Nasrin Talischy, Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood. ,vol. 99, pp. 3905- 3908 ,(2002) , 10.1182/BLOOD.V99.11.3905
Y Kobayashi, M Ohtsuki, T Murakami, T Kobayashi, K Sutheesophon, H Kitayama, Y Kano, E Kusano, H Nakagawa, Y Furukawa, Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma. Oncogene. ,vol. 25, pp. 512- 524 ,(2006) , 10.1038/SJ.ONC.1209072
Yogen Saunthararajah, Cheryl A. Hillery, Don Lavelle, Robert Molokie, Louise Dorn, Linda Bressler, Stefana Gavazova, Yi-Hsiang Chen, Ronald Hoffman, Joseph DeSimone, Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease Blood. ,vol. 102, pp. 3865- 3870 ,(2003) , 10.1182/BLOOD-2003-05-1738
R. Abele, M. Clavel, P. Dodion, U. Bruntsch, S. Gundersen, J. Smyth, J. Renard, M. Van Glabbeke, H.M. Pinedo, The EORTC early clinical trials cooperative group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas European Journal of Cancer and Clinical Oncology. ,vol. 23, pp. 1921- 1924 ,(1987) , 10.1016/0277-5379(87)90060-5
Maika Almstedt, Nadja Blagitko-Dorfs, Jesús Duque-Afonso, Julia Karbach, Dietmar Pfeifer, Elke Jäger, Michael Lübbert, The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leukemia Research. ,vol. 34, pp. 899- 905 ,(2010) , 10.1016/J.LEUKRES.2010.02.004